[THE INVESTOR] Samsung BioLogics announced on Sept. 7 that it received six manufacturing licenses from the European Medicines Agency and the US Food and Drug Administration.

Samsung BioLogics is the world’s third largest biologics contract manufacturer by capacity.

With the latest licenses, Samsung BioLogics now has seven production licenses. 



A contract manufacturer is required to obtain production licenses before operations can begin regardless of whether the product has been approved by the authorities.

By Choi He-suk (cheesuk@heraldcorp.com)